evidence based medicine pharmacological treatment of alcohol dependence
TRANSCRIPT
Evidence Based MedicineEvidence Based Medicine
Pharmacological Treatment of Pharmacological Treatment of Alcohol DependenceAlcohol Dependence
Case PresentationCase Presentation
49yo m with HTN, HLP, DM2 presents to clinic for possible medical treatment for his 20 year h/o chronic alcohol use. He drinks about 6-12pack/day. Denies any legal problems. Retired. Wife recently divorced him secondary to issues that could be related to his alcohol use.
He has been sober for a week now “cold turkey.” He has some urges/cravings and His friend from the VFW got medicine that helped him with that. He was wondering if I could prescribe him something similar.
Question?Question?
Can a pharmacotherapy approach (I.e “medical management”) be used to treat alcohol dependence?
(I.e. can I try to treat him myself?)Should I refer AND medicate, or just refer?
Alcohol BackgroundAlcohol Background
100,000 deaths annually in US 30% of all traffic fatalities Affect 10% of Americans at some point in their
lives 2002 survey of 43,000 adults – prevalence about
12.5%(1) 2006 Survey of 2,397 EM residents (2)
– 3.3% daily drinkers– 12.6% increased consumption during residency
DefinitionDefinition
Alcohol Dependence per DSMIV : 3+– Tolerance– Withdrawal (E) – Substance taken in larger quantities than intended– Persistent desire to cut down or control use (C )– Time is spent obtaining, using or recovering (G)– Social, occupational or recreational tasks are sacrificed (AG?)– Use continues despite physical and psychological problems
(G?)
AlcoholAlcohol
GABA (stim, sedate, intoxicate)GLUTAMATE (stim, sedate, intoxicate)
DOPAMINE (reinforce, reward, craving)OPIATE (reinforce, reward, craving)
How it works?How it works?
What about medicines?What about medicines?
US FDA approval– Disulfiram (antabuse)– Naltrexone (Vivitrol 380mg IM q4week or
ReVia 50mg po qday)– Acamprosate(Campral) 666mg to 1g po tid
Disulfiram (antabuse)Disulfiram (antabuse)
Disulfiram DataDisulfiram Data
Double blind trial – “core journals” 1 trial1986 JAMA – VA CoOp study
– 605 patients randomized + CBT 250mg disulfiram 1mg disulfiram Nothing
DisulfiramDisulfiram Data Data
80% noncompliant– 10% abstinent rate
20% Compliant– 50% abstinent
NO difference in time to first drink, abstinent days,
patients in the 250mg Disulfiram group did drink less.
No difference at 1 year follow up.
Disulfiram Other studiesDisulfiram Other studies
Author, Yr Follow-up Disulfiram Abstinence
Gerrein, 1973 85%, 39%
MonitoredUnmonitored
40%
7%
Azrin, 1976 90% Monitored 90-98%
Azrin, 1982 100% Monitored 73%*
Liebson, 1978 78% Monitored 98%
Disulfiram SummaryDisulfiram Summary
Works well when patients are compliant.– (i.e not very good for outpt use)
Use if goal is zero alcohol use.Warn patients when using other products
that may contain alcohol (mouthwash, etc,.)
NaltrexoneNaltrexone
Opioid receptor antagonist, can blunt the pleasurable effects and reduce cravings
Can’t use in patients taking chronic opiatesHepatotoxicity
~homotaurine ~GABA (gamma aminobutyric acid)
Decrease excitatory glutamergic neurotransmission during alcohol withdrawal, and reduce cravings
Usual dose is 666mg po tidRenally cleared so c/i in renal disease.FDA approved in 2004
AcamprosateAcamprosate
SearchSearch
Pubmed search– 1996-present RCT, CT ‘naltrexone +
alcoholism’– 1996-present RCT, CT ‘camprosate +
alcoholism’Results:
Acamprosate – 1996 LancetVA study Naltrexone 2001
COMBINE study 2006
AcamprosateAcamprosate(Whitworth et al, Lancet 1996)(Whitworth et al, Lancet 1996)
Multicenter, DBPCT 448 Adult patients Randomized to
– 1998 mg (666mg tid) – Placebo
F/u 0, 30, 90, 180, 270 and 360 days Primary Outcome
– Time to treatment Failure (relapse or non attendance)
Acamprosate ResultsAcamprosate Results
448 patients– 224 acamprosate arm
94 completed 52 withdrawn, 33 lost to f/u, 31 refused, 15 ill, 2died 6 side effects
– 224 placebo arm 85 completed 52 withdrawn, 36 lost to f/u, 32 refused, 11 ill, 1died 4 side effects
Acamprosate ResultsAcamprosate Results
At end of study – Day 360– Abstinent
41/224 (18.3%) abstinent 16/224 (7.1%) abstinent, (p=0.007)
– Mean abstinent duration 138.8 days vs 103 days (p=0.012) not significant
11% (1 in 9 NNT) to get abstinent
2001. Multicenter – RCT 627 Veterans with alcohol dependence
– 12months naltrexone 50mg a day– 3monts of naltrexone then placebo 9months– 12months placebo– +Counseling
Primary Outcome– Time to relapse (I.e 1st day of heavy drinking)– Number of drinks/day
VA - DemographicsVA - Demographics
ComplianceCompliance
OutcomeOutcome
VA SummaryVA Summary
Pt population of mainly men (97%), avg 13drinks/day, started drinking regular at 23.
Naltrexone 50mg a day + therapy– Not different than placebo in
Time to relapse Calendar days drinking
Naltrexone (Cochrane 2005)Naltrexone (Cochrane 2005)
27 RCT12 weeks of Naltrexone
– Decreases relapse 36%– Reduce the chance of returning to drink 13%
Faults – short duration, small sizes.
11sites, 1383 patients, alcohol dependenceExcluded patients with other drug use (x/c cannabis)Avg age 44, avg 12drinks/day, 67%men, 40%married4 days abstinence then ->Randomized (naltrexone 100mg/day, acamprosoate 666mg tid)
MM – 9 sessions/16weeks, and at 26,52,68 weeks(0,1,2,4,6,8,10,12,16 week)
CBT – alcohol specialistAlcohol use was self reported and verified by level of %CDT (abnormal
serum transferrin protein) End Point - % days abstinent, time to >1 heavy drinking days (>5 men
>4women)
COMBINE COMBINE –– arms arms
“Good clinical outcome” – – no more than 2days of heavy drinking per week, – (14drinks per week/men 11drink/women) – and without alcohol related problems
COMBINE SUMMARYCOMBINE SUMMARY
Combined therapy - no additive benefit.Acamprosate not statistically beneficial.Naltrexone
– %days abstinent 80.6% vs 75.1% = p=.009– Heavy drinking day (66.2% vs 73.1%) p=0.15– “Good clinical outcome” – 73.7% vs 58.2%
CostsCosts
Disulfiram – 250mg po qday/month $112.00 ($77.70 CHCS)
Naltrexone – 50mg po qday/month $205.00, $18.00 generic
(CHCS)– 380mg IM q month. $504.40 (CHCS)
Acamprosate– 333mg po tid/month - $150.00 ($30.00 CHCS)
NMCSD Formulary?NMCSD Formulary?
We carry all meds but restricted to SARP / Psychiatry
SummarySummary
Disulfiram helpful in a monitored settingNaltrexone data conflicting
– Reviews show helpful short term. – VA DBCT – not helpful at 50mg for one year– COMBINE study – benefit at 100mg
Camprosate– Benefit with CBI at one year– COMBINE study – showed no benefit
Follow upFollow up
Checked labs (LFT, CBC, B12, Folate, TSH) were normal
Recommended AA treatment– www.aa.org
Questions?Questions?